GBG Research at ESMO Breast Cancer 2019

#1080: Factors predicting relapse in early breast cancer patients with a pathological complete response after neoadjuvant therapy: pooled analysis based on the GBG database

• Session: Type: Proffered Paper session; Title: Best abstracts session; 3.05.2019, 16:45 - 17:00 (oral presentation)
• First author: J. Huober J; Universitätsfrauenklinik Ulm, Germany

#15P: Influence of PIK3CA mutations on breast cancer proliferation, lymphocyte infiltration and clinical outcome: pooled analysis of 484 patients from three prospective multicentre GBG trials

• Session: Type: Poster display session; Title: Poster lunch; 3.05.2019, 12:15 - 13:00 (poster)
• First author: P. Jank; Charité Universitaetsmedizin Berlin, Germany

#25P: Expression of ER, PR, HER2 and Ki-67 in the neoadjuvant GeparX trial - comparison of central immunohistochemistry (IHC) with an automated cartridge-based system for mRNA assessment

• Session: Type: Poster display session; Title: Poster lunch; 03.05.2019; 12:15 - 13:00 (poster)
• First author: C. Denkert; Institut für Pathologie Philipps-Universität Marburg, Germany

#122TiP: GeparDouze/NSABP B-59: A randomized double-blind phase III clinical trial of neoadjuvant chemotherapy with atezolizumab or placebo in patients with triple negative breast cancer (TNBC) followed by adjuvant atezolizumab or placebo

• Session: Early breast cancer: Neoadjuvant therapy; 3.05.2019; 12:15 – 13:00 (poster, trial in progress)
• First author: S. Loibl; GBG, Neu-Isenburg, Germany

https://www.esmo.org/Conferences/ESMO-Breast-Cancer-2019/Programme